Simple search of free and LexisNexis legal content for Australia
– legislation, cases, practical guidance, forms & precedents, journals and newsletters.
Reckitt Benckiser (Australia) Pty Ltd V Glaxosmithkline Australia Pty LtdFederal Court of Australia
Judgment Date: 2018-08-24
Abstract: A comparative advertising campaign in which Reckitt Benckiser (Australia) Pty Ltd compared its product Nurofen and its active ingredient ibuprofen with a competing product, Panadol and its active ingredient paracetamol, was found to be misleading or deceptive, or likely to mislead or deceive. The Federal Court of Australia Full Court affirmed the Federal Court of Australia's findings that the balance of scientific evidence demonstrated no clear-cut superiority of ibuprofen over paracetamol in terms of faster and more effective relief from pain caused by common headaches.
Trade and commerce | Trade practices | Advertising | Misleading and deceptive conduct
Published: 14/09/2018
|
LexisNexis® LegalExpress
|